---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-427224"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2026-10-21T12:07:22+00:00"
generated_at: "2026-10-21T12:10:04.466852+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics names Robin Swartz President; slated to succeed CEO Sandrock after Q1 2027 VY1706 safety data

## Summary
- Swartz, 56, becomes President effective Oct 20, 2026; she has been COO and Chief Business Officer since Nov 2024 and Principal Financial Officer/Treasurer since May 2026.
- CEO transition expected after initial acute safety data from the VY1706 trial in early Alzheimer's, anticipated in Q1 2027; Alfred Sandrock is expected to remain on the Board.
- Swartz base salary $625,000 with a 50% target bonus; she receives an option for 318,500 shares and 68,250 RSUs granted Nov 1, 2026 under the 2025 Stock Incentive Plan.
- Severance on termination without cause or for good reason: 12 months base salary, pro rata target bonus and up to 12 months COBRA; full equity acceleration if within 12 months after a sale event.

## SEC filing metadata
- accession: 0001193125-26-427224
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2026-10-21T12:07:22+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/0001193125-26-427224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000119312526427224/d157795d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-427224
- JSON: https://secwatch.observer/filing/0001193125-26-427224.json
- Plain text: https://secwatch.observer/filing/0001193125-26-427224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.